Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib after osimertinib resistance in EGFR-mutant advanced NSCLC
ChiCTR2100049904Phase 2Not yet recruiting
- Sponsor
- Jinshan Hospital of the First Affiliated Hospital of Chongqing Medical University
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Jinshan Hospital of the First Affiliated Hospital of Chongqing Medical University. Primary endpoints: objective response rate, progression-free survival and 1 more. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100049904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049904.